Evercore ISI Group analyst Mark Mahaney maintains Meta Platforms (NASDAQ:META) with a Outperform and lowers the price target from $325 to $280.
Rain Therapeutics Experimental Cancer Therapy Shows Encouraging Tumor Regression Activity
Rain Therapeutics Inc (NASDAQ:RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors. “Treatment…